Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States

Michael R. Charlton, Justin M. Burns, Rachel A. Pedersen, Kymberly D. Watt, Julie K. Heimbach, Ross A. Dierkhising

Research output: Contribution to journalArticle

616 Citations (Scopus)

Abstract

Background & Aims: The relative frequency of nonalcoholic steatohepatitis (NASH) as an indication for liver transplantation and comparative outcomes following transplantation are poorly understood. Methods: We analyzed the Scientific Registry of Transplant Recipients for primary adult liver transplant recipients from 2001 to 2009. Results: From 2001 to 2009, 35,781 patients underwent a primary liver transplant, including 1959 for who NASH was the primary or secondary indication. The percentage of patients undergoing a liver transplant for NASH increased from 1.2% in 2001 to 9.7% in 2009. NASH is now the third most common indication for liver transplantation in the United States. No other indication for liver transplantation increased in frequency during the study period. Compared with other indications for liver transplantation, recipients with NASH are older (58.5 ± 8.0 vs 53.0 ± 8.9 years; P <.001), have a larger body mass index (>30 kg/m 2) (63% vs 32%; P <.001), are more likely to be female (47% vs 29%; P <.001), and have a lower frequency of hepatocellular carcinoma (12% vs 19%; P <.001). Survival at 1 and 3 years after liver transplantation for NASH was 84% and 78%, respectively, compared with 87% and 78% for other indications (P =.67). Patient and graft survival for liver recipients with NASH were similar to values for other indications after adjusting for level of creatinine, sex, age, and body mass index. Conclusions: NASH is the third most common indication for liver transplantation in the United States and is on a trajectory to become the most common. Outcomes for patients undergoing a liver transplant for NASH are similar to those for other indications.

Original languageEnglish (US)
Pages (from-to)1249-1253
Number of pages5
JournalGastroenterology
Volume141
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Liver Transplantation
Liver
Transplants
Non-alcoholic Fatty Liver Disease
Graft Survival
Registries
Hepatocellular Carcinoma
Creatinine
Body Mass Index
Transplantation
Survival

Keywords

  • Complications of Obesity
  • Liver Disease
  • Organ Transplantation
  • Steatosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Charlton, M. R., Burns, J. M., Pedersen, R. A., Watt, K. D., Heimbach, J. K., & Dierkhising, R. A. (2011). Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology, 141(4), 1249-1253. https://doi.org/10.1053/j.gastro.2011.06.061

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. / Charlton, Michael R.; Burns, Justin M.; Pedersen, Rachel A.; Watt, Kymberly D.; Heimbach, Julie K.; Dierkhising, Ross A.

In: Gastroenterology, Vol. 141, No. 4, 10.2011, p. 1249-1253.

Research output: Contribution to journalArticle

Charlton, MR, Burns, JM, Pedersen, RA, Watt, KD, Heimbach, JK & Dierkhising, RA 2011, 'Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States', Gastroenterology, vol. 141, no. 4, pp. 1249-1253. https://doi.org/10.1053/j.gastro.2011.06.061
Charlton, Michael R. ; Burns, Justin M. ; Pedersen, Rachel A. ; Watt, Kymberly D. ; Heimbach, Julie K. ; Dierkhising, Ross A. / Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. In: Gastroenterology. 2011 ; Vol. 141, No. 4. pp. 1249-1253.
@article{ae12d82d23e745baa17c27798c088987,
title = "Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States",
abstract = "Background & Aims: The relative frequency of nonalcoholic steatohepatitis (NASH) as an indication for liver transplantation and comparative outcomes following transplantation are poorly understood. Methods: We analyzed the Scientific Registry of Transplant Recipients for primary adult liver transplant recipients from 2001 to 2009. Results: From 2001 to 2009, 35,781 patients underwent a primary liver transplant, including 1959 for who NASH was the primary or secondary indication. The percentage of patients undergoing a liver transplant for NASH increased from 1.2{\%} in 2001 to 9.7{\%} in 2009. NASH is now the third most common indication for liver transplantation in the United States. No other indication for liver transplantation increased in frequency during the study period. Compared with other indications for liver transplantation, recipients with NASH are older (58.5 ± 8.0 vs 53.0 ± 8.9 years; P <.001), have a larger body mass index (>30 kg/m 2) (63{\%} vs 32{\%}; P <.001), are more likely to be female (47{\%} vs 29{\%}; P <.001), and have a lower frequency of hepatocellular carcinoma (12{\%} vs 19{\%}; P <.001). Survival at 1 and 3 years after liver transplantation for NASH was 84{\%} and 78{\%}, respectively, compared with 87{\%} and 78{\%} for other indications (P =.67). Patient and graft survival for liver recipients with NASH were similar to values for other indications after adjusting for level of creatinine, sex, age, and body mass index. Conclusions: NASH is the third most common indication for liver transplantation in the United States and is on a trajectory to become the most common. Outcomes for patients undergoing a liver transplant for NASH are similar to those for other indications.",
keywords = "Complications of Obesity, Liver Disease, Organ Transplantation, Steatosis",
author = "Charlton, {Michael R.} and Burns, {Justin M.} and Pedersen, {Rachel A.} and Watt, {Kymberly D.} and Heimbach, {Julie K.} and Dierkhising, {Ross A.}",
year = "2011",
month = "10",
doi = "10.1053/j.gastro.2011.06.061",
language = "English (US)",
volume = "141",
pages = "1249--1253",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States

AU - Charlton, Michael R.

AU - Burns, Justin M.

AU - Pedersen, Rachel A.

AU - Watt, Kymberly D.

AU - Heimbach, Julie K.

AU - Dierkhising, Ross A.

PY - 2011/10

Y1 - 2011/10

N2 - Background & Aims: The relative frequency of nonalcoholic steatohepatitis (NASH) as an indication for liver transplantation and comparative outcomes following transplantation are poorly understood. Methods: We analyzed the Scientific Registry of Transplant Recipients for primary adult liver transplant recipients from 2001 to 2009. Results: From 2001 to 2009, 35,781 patients underwent a primary liver transplant, including 1959 for who NASH was the primary or secondary indication. The percentage of patients undergoing a liver transplant for NASH increased from 1.2% in 2001 to 9.7% in 2009. NASH is now the third most common indication for liver transplantation in the United States. No other indication for liver transplantation increased in frequency during the study period. Compared with other indications for liver transplantation, recipients with NASH are older (58.5 ± 8.0 vs 53.0 ± 8.9 years; P <.001), have a larger body mass index (>30 kg/m 2) (63% vs 32%; P <.001), are more likely to be female (47% vs 29%; P <.001), and have a lower frequency of hepatocellular carcinoma (12% vs 19%; P <.001). Survival at 1 and 3 years after liver transplantation for NASH was 84% and 78%, respectively, compared with 87% and 78% for other indications (P =.67). Patient and graft survival for liver recipients with NASH were similar to values for other indications after adjusting for level of creatinine, sex, age, and body mass index. Conclusions: NASH is the third most common indication for liver transplantation in the United States and is on a trajectory to become the most common. Outcomes for patients undergoing a liver transplant for NASH are similar to those for other indications.

AB - Background & Aims: The relative frequency of nonalcoholic steatohepatitis (NASH) as an indication for liver transplantation and comparative outcomes following transplantation are poorly understood. Methods: We analyzed the Scientific Registry of Transplant Recipients for primary adult liver transplant recipients from 2001 to 2009. Results: From 2001 to 2009, 35,781 patients underwent a primary liver transplant, including 1959 for who NASH was the primary or secondary indication. The percentage of patients undergoing a liver transplant for NASH increased from 1.2% in 2001 to 9.7% in 2009. NASH is now the third most common indication for liver transplantation in the United States. No other indication for liver transplantation increased in frequency during the study period. Compared with other indications for liver transplantation, recipients with NASH are older (58.5 ± 8.0 vs 53.0 ± 8.9 years; P <.001), have a larger body mass index (>30 kg/m 2) (63% vs 32%; P <.001), are more likely to be female (47% vs 29%; P <.001), and have a lower frequency of hepatocellular carcinoma (12% vs 19%; P <.001). Survival at 1 and 3 years after liver transplantation for NASH was 84% and 78%, respectively, compared with 87% and 78% for other indications (P =.67). Patient and graft survival for liver recipients with NASH were similar to values for other indications after adjusting for level of creatinine, sex, age, and body mass index. Conclusions: NASH is the third most common indication for liver transplantation in the United States and is on a trajectory to become the most common. Outcomes for patients undergoing a liver transplant for NASH are similar to those for other indications.

KW - Complications of Obesity

KW - Liver Disease

KW - Organ Transplantation

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=80053581540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053581540&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2011.06.061

DO - 10.1053/j.gastro.2011.06.061

M3 - Article

C2 - 21726509

AN - SCOPUS:80053581540

VL - 141

SP - 1249

EP - 1253

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -